During an unprecedented year, Rentschler Biopharma continued to meet the demands of its core protein therapeutic business while expanding into novel therapeutics. The CDMO continues to expand and innovate beyond the pandemic by pioneering digitized processes and adding capabilities in response to client needs. The company offers services along the entire biopharmaceutical value chain — via both in-house expertise and an array of best-in-class strategic alliance partners.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Federico Pollano
Finding the Sweet Spot With Biosimilars and mAbs
Federico Pollano is Senior Vice President at Rentschler Biopharma, located in Laupheim, Germany. He has almost 30 years of experience in pharmaceuticals and biopharmaceuticals, mainly in senior and executive positions, at the following companies; Polpharma Biologics, Richter-Helm BioTec, Helm, BioGenerix, Glaxo Wellcome and Zambon. Pollano studied biology at Bielefeld University, Germany, and at the German Primate Center, Göttingen.
Driving Innovation to Support Strategic Client Partnerships
Patients have been benefiting from the innovative nature of the pharmaceutical industry for over a century. With an increased reliance on outsourcing, contract development and manufacturing organizations focused on bringing cutting-edge solutions to the market have a distinct competitive advantage, and Rentschler Biopharma has been at the forefront of biologic development and manufacturing for over 40 years.
Q: How important are international partnerships (with sponsor firms, service providers, engineering firms, equipment vendors, raw material suppliers, etc.) to your success?
International Partnerships Ashleigh Wake, Director of Biological Services, Intertek Pharmaceutical ServicesA: Success in international markets is fundamental to the progression and growth of our pharmaceutical business. This demographic is driven by the geography of the market itself, in terms of current global pharmaceutical consumption and predicted regional growth, as well as the regulatory requirement for regional testing to support global and local product registration.
Rentschler Biopharma SE Sets Foot in the U.S. to Strengthen its World-Class CDMO Position
The biopharmaceutical industry is undergoing significant change. To remain successful in an evolving marketplace, a biopharmaceutical contract development and manufacturing organization (CDMO) must think strategically and anticipate future client demands to determine how to best provide the novel technologies and regional capabilities that will be required going forward.
Dedicated CDMO Services Meet Customer Needs in the Dynamic Biopharma Sector
Industry Leader Insight Biopharmaceutical drug developers are increasingly relying on contract development and manufacturing organizations (CDMOs) to provide the specialized knowledge, expertise and technologies required to accelerate the development and commercialization of these important medicines.
A World-Class Biopharmaceutical CDMO - BioProcess International
Rentschler Biopharma SE — located in Laupheim, Germany — is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company’s clients include innovative biotech companies and major pharmaceutical companies around the world. Rentschler Biopharma has long-standing experience and proven excellence as a solution partner of choice.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Federico
Contact Federico, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack